e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Biomarkers for lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Presence of volatile organic compounds (VOC) in exhaled breath in patients diagnosed with lung cancer (LC) vs healthy patients. Preliminary data
A. Muñoz Lucas, M. Caamaño Somoza, J. Jareño Esteban, I. de Granda Orive, B. Carrillo Aranda, J. A. Maldonado Sanz, A. Aguilar Ros, C. Civera Tejuca, J. L. Lopez Colon, L. M. Callol Sanchez (Madrid, Spain)
Source:
Annual Congress 2010 - Biomarkers for lung cancer
Session:
Biomarkers for lung cancer
Session type:
Thematic Poster Session
Number:
3245
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Muñoz Lucas, M. Caamaño Somoza, J. Jareño Esteban, I. de Granda Orive, B. Carrillo Aranda, J. A. Maldonado Sanz, A. Aguilar Ros, C. Civera Tejuca, J. L. Lopez Colon, L. M. Callol Sanchez (Madrid, Spain). Presence of volatile organic compounds (VOC) in exhaled breath in patients diagnosed with lung cancer (LC) vs healthy patients. Preliminary data. Eur Respir J 2010; 36: Suppl. 54, 3245
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
Detection of differences in volatile organic compounds (VOCs) by ion mobility spectrometry (IMS) of exhaled breath in patients with interstitial lung diseases (ILDs) compared to healthy controls (HC)
Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Year: 2011
Electronic nose (E-nose) analysis of exhaled volatile organic compounds (VOCs) distinguishes pediatric patients (pts) with Cystic fibrosis (CF) from healthy controls (HC) and depicts disease status
Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Year: 2020
Volatile organic compounds (VOCs) in exhaled air of patients with lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 208s
Year: 2003
Volatile organic compounds (VOC) in exhaled breath of patients with COPD
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases
Year: 2010
Differences in volatile organic compounds (VOC) determined in exhaled breath in two populations of lung cancer (LC): With and without COPD
Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer
Year: 2013
Volatile organic compounds (VOC) in exhaled air sampled through the working channel of a bronchoscope in lung cancer patients
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Volatile organic compounds (VOC) in exhaled breath in patients with lung cancer, using the analytical technique thermal desorber- gase chromatography-spectrometer mases
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Breath volatile organic compound (VOC) patterns in adult asthma patients of the ALLIANCE cohort
Source: International Congress 2019 – Evaluation of basic science in airway diseases
Year: 2019
Volatile organic compounds (VOCs) in COPD patients with exacerbation
Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Year: 2011
Analysis of semi-volatile organic compounds in exhaled breath condensate of patients with obstructive lung diseases
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
Early detection of lung cancer through analysis of VOC biomarkers in exhaled breath: The LuCID study.
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017
Integrating monitoring of volatile organic compounds (VOCs) in asthma and COPD into the routine lung function
Source: International Congress 2015 – The next generation of lung function tests
Year: 2015
Expiratory flow rate and breath hold affect exhaled volatile organic compounds (VOC) in healthy subjects
Source: Annual Congress 2012 - Exhaled biomarkers to assess airway inflammation
Year: 2012
Volatile organic compounds (VOC) in non-small-cell lung cancer (NSCLC)
Source: Annual Congress 2010 - The role of biomarkers in lung cancer
Year: 2010
Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort
Source: Eur Respir J, 57 (2) 2002127; 10.1183/13993003.02127-2020
Year: 2021
Volatile organic compounds in exhaled breath of patients with COPD ± lung cancer and their correlation with FEV1-values
Source: International Congress 2014 – The assessment of comorbidities
Year: 2014
New contributions in the determination of volatile organic compounds (VOC) in lung cancer (LC)
Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer
Year: 2011
The clinical significance of growth factors measurement in exhaled breath condensates (EBC) among patients with interstitial lung diseases
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
Identification of exhaled volatile organic compounds (VOCs) associated with loss of asthma control
Source: International Congress 2016 – Assessing lower airway inflammation with different tools
Year: 2016
Detection and variability of cytokine-levels in exhaled breath condensate (EBC) of patients with stable COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 438s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept